trastuzumab deruxtecan,ruxolitinib
novartis,daiichi sankyo,astrazeneca,incyte
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rux,(-crux),(-trux)', 'destiny,crc,02', 'trastuzumab deruxtecan']
dr. raghav presenting awaiting data from destiny crc02 in her2+ mcrc; different doses of trastuzumab deruxtecan explored, and pts with ras wt/mutant tumors both included #asco2023 #asco23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.